晚期非小细胞肺癌中ERCC1蛋白表达与铂类化疗药物敏感性的关系  

Relationship between the Expression of ERCC1 and Chemotherapeutic Effect with Platinum-based Chemotherapy in Advanced Non-small-cell Lung Cancer with Different Tissue Types

作　　者：伍建蓉[1] 郑玲[1] 谷焰[1] 王晓毓[1] 白娟[1] 

机构地区：[1]成都大学附属医院肿瘤科,610081

出　　处：《实用癌症杂志》2012年第6期574-577,共4页The Practical Journal of Cancer

摘　　要：目的探讨晚期非小细胞肺癌(NSCLC)中核苷酸切除修复交叉互补基因(ERCC1)的表达及其与铂类化疗药物疗效的相关性。方法采用免疫组化S-P法,检测69例Ⅲ、Ⅳ期非小细胞肺癌中ERCC1蛋白表达。所有患者采用以铂类为基础的方案化疗。结果 69例晚期NSCLC组织中ERCC1蛋白表达阳性率为39.13%(27/69),鳞癌为41.94%(13/31),腺癌为36.84%(14/38),ERCC1蛋白表达阳性率与肿瘤组织学类型无关(χ2=0.1859,P=0.6663)。鳞癌患者ERCC1蛋白表达阴性者化疗有效率为44.44%,ERCC1阳性者化疗有效率为7.69%,两者比较差异有统计学意义(P=0.0448);腺癌患者ERCC1表达阴性者化疗有效率为33.33%,ERCC1表达阳性者化疗有效率为21.43%,两者比较差异无统计学意义(P=0.4882)。不论鳞癌还是腺癌患者,ERCC1表达对患者生存期均无明显影响(P均>0.05)。结论 ERCC1蛋白表达与晚期NSCLC患者的化疗疗效密切相关,尤其是鳞癌患者。Objective To explore the relationship between the expression of excision repair cross-completion1（ERCC1）and the curative effect of platinum-based chemotherapy in patients with advanced non-small cell Lung Cancer（NSCLC）.Methods The expression of ERCC1 was examined by immunohistochemical technique in 69 patients with advanced NSCLC.All patients were treated with platinum-based chemotherapy.Results The expression of ERCC1 was 39.13% among 69 cases,and there was no correlation with pathology type.The response rate（CR＋PR） in ERCC1 positive patients of squamocellular cancer was obviously lower than that in ERCC1 negative patients（7.69% vs 44.44%,P=0.0448）,the response rate（CR＋PR） in ERCC1 positive patients of gland cancer was lower than that in ERCC1 negative patients（21.43%vs 33.33%）,but P0.05.The expression of ERCC1 has no obvious influence on the survival data of patients with squamocellular cancer or gland cancer.Conclusion The expression of ERCC1 protein is closely related to the response to chemotherapy of patients with advanced NSCLC,specially the patients of squamocellular cancer.

关 键 词：非小细胞肺癌 ERCC1蛋白 免疫组织化学 化疗 

分 类 号：R734.2[医药卫生—肿瘤]